The versions affected are called compounded medications, which have the same active ingredients as the name brands. The ...

Novo Nordisk shares rose Monday as the company said it would present new data on the ability of semaglutide, the active ...

The makers of weight-loss drugs Wegovy and Zepbound are lowering prices significantly, effective immediately, to make them more affordable.

He and his team then compared the diagnoses for hair loss in these patients’ medical records and found that those prescribed ...

Eli Lilly launched its blockbuster diabetes and weight-loss drug Mounjaro in India on Thursday, beating rival Novo Nordisk ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

Novo Nordisk may be reorganizing its early-stage R&D capabilities, but the Danish pharma’s chief scientific officer has insisted that the changes aren’t primarily about laying off staff. | Novo ...

Shares of Novo Nordisk fell sharply on Monday, after the firm published results from the latest clinical trial of its CagriSema weight-loss drug.

The FDA wants bulk production of copycat versions of popular weight-loss drugs to stop, but telehealth companies and compounding pharmacies ...

The setback comes at a crucial time for Novo Nordisk, which had positioned CagriSema as its next-generation weight-loss ...

A new study suggests blockbuster weight loss drugs Wegovy and Zepbound are not cost-effective at their current prices, despite the proven health benefits. The study, published in JAMA Health Forum and ...

Novo Nordisk has lowered Wegovy's monthly cost by 23%, and Eli Lilly cut prices for Zepbound's starter dose to $349 per month. HealthDay News — The makers of two popular weight-loss drugs — Wegovy and ...